Opendata, web and dolomites


A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa

Total Cost €


EC-Contrib. €






Project "PAVax" data sheet

The following table provides information about the project.


Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙054˙239 €
 EC max contribution 1˙054˙239 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-EID
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2024-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 531˙239.00
2    GLAXOSMITHKLINE VACCINES SRL IT (SIENA) participant 522˙999.00


 Project objective

PAVax is a network that will train 4 early-stage researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic resistant bacterium Pseudomionas aeruginosa (PA), for which there currently is no adequate vaccine available. This consortium will explore and exploit the use of PA-exopolysaccharides that play a key role in biofilm formation that protects the bacterium from its environment: alginate, Psl and Pel. We will exploit these saccharides to generate novel vaccines targeting these exposed polysaccharides. Next to the isolation of these polysaccharides from the bacteria, we will employ synthetic chemistry to deliver well-defined fragments of these polysaccharides. These will be used to map the interactions of the saccharides with antibodies to inform on the structure of the optimal epitope. We will conjugate the (synthetic) fragments to newly discovered PA proteins to generate conjugate vaccines targeting multiple PA entities. The consortium is formed by an academic partner, Leiden University (NL) and an industrial partner, GSK Vaccines, Siena (IT), harnessing the complementary expertise of both partners to achieve the ambitious goals set. The close collaboration between the two partners will ensure training of the ESRs at the highest level and best synergy possible. The ESRs will receive intersectorial, international and interdisciplinary training in (synthetic) carbohydrate chemistry, vaccine design, protein chemistry and conjugation, biophysical interaction studies, and immunology. With the ever-growing awareness of the importance of carbohydrates in health and disease, and the continuous threat of multidrug resistant bacteria, the skill set acquired by the ESRs will prepare them to face the major scientific and societal challenges ahead and become important players in academic or industrial research in the future

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SECRET (2019)

Exploitation of the SECRETory pathway for cancer therapy to address European research

Read More  

LIVE-I (2020)

Lightening and Innovating transmission for improving Vehicle: Environmental Impacts

Read More  

RNAct (2019)

Enabling proteins with RNA recognition motifs for synthetic biology and bio-analytics.

Read More